Description
EFFERFLU C IMMUNE BOOSTER
EFFERFLU C IMMUNE BOOSTER
R79,99
Pages
- #98 (no title)
- Aiforia deal to expand access to pathology AI
- Amphista doses first patient in AML trial of protein degrader
- Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
- Appointment
- Astoriom acquires Sampled’s UK stability storage operations
- AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
- AstraZeneca’s Trixeo approved in EU for asthma
- AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
- Bio-Techne opens GMP small-molecule manufacturing facility in Bristol
- bit.bio expands human heart cell portfolio through myriamed partnership
- Blood sensor detects Parkinson’s-associated proteins in 40 minutes
- Bramacare opens supported-living facility for eating disorder recovery
- Brenntag and dsm-firmenich expand biopharma vitamin partnership
- Cart
- CeramTec expands German production capacity for orthopaedic ceramics
- Charity commits £800,000 to AI research into late breast cancer recurrence
- Checkout
- Claris reports visual acuity gains with experimental LSCD treatment
- Contact us
- Cori Clinical raises US$4m to expand AI platform for clinical trial design
- Danish medical cannabis use rises as regulator reports no new safety signals
- Daynite Pharmacy
- Digital platform cuts pharmaceutical quality-record approval times by up to 90%
- Elementor #22
- Elementor #75
- ESTEVE CDMO adds $17.5m to Illinois expansion
- Femtosecond laser cuts lung tumour margin assessment time
- First 90 days of antipsychotic treatment linked to rapid metabolic changes
- Global coalition calls for stronger government action on COPD
- Home
- Hot-tub therapy tested as potential treatment for peripheral artery disease
- Migraine annual economic and quality-of-life burden in UK
- Most advanced breast cancer patients treated in community settings, Phesi study finds
- My account
- NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
- NIHR chief scientific adviser visits Huddersfield health innovation campus
- Ofichem acquires US drug substance CDMO Kinentia
- One in three UK women with migraine say symptoms taken less seriously
- Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
- Pharmacy Services
- Phoenix Labs acquires Kent Pharma
- Refund and Returns Policy
- Register Login user
- Report highlights scope to expand day surgery
- Shop
- SMC accepts atogepant for acute migraine treatment in Scotland
- Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia
- Sterling doubles ADC manufacturing capacity at Welsh facility
- Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
- Tridem begins phase Ib trial of Parkinson’s disease vaccine
- UK immunoglobulin supply faces growing pressure, report warns
- Welcome
Archives
Categories
- Uncategorized (1)
Reviews
There are no reviews yet.